ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

VOLTAREN OPH SOLN
Ocular allergy/inflammation
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

VOLTAREN OPH SOLN Rx

Generic Name and Formulations:
Diclofenac sodium 0.1%.

Company:
Novartis Ophthalmics

Therapeutic Use:

Indications for VOLTAREN OPH SOLN:

Post-op inflammation after cataract extraction. Photophobia and pain in corneal refractive surgery.

Adult:

Cataract surgery: 1 drop 4 times daily beginning 24 hrs post-op for 2 weeks. Corneal refractive surgery: 1–2 drops within the hour prior to surgery, then within 15 minutes post-op, then 4 times daily for up to 3 days.

Children:

Not established.

Warnings/Precautions:

Bleeding tendencies. Complicated or repeat ocular surguries. Corneal defects/denervation. Ocular surface diseases. Rheumatoid arthritis. Diabetes. May delay wound healing. Monitor cornea; discontinue if corneal epithelial breakdown occurs. Should not be used by patients currently wearing soft contact lenses. Monitor refractive stability for 1 year. Pregnancy (Cat.C); avoid during late pregnancy. Nursing mothers: not recommended.

Interactions:

Caution with medications that prolong bleeding time. Concomitant use of topical steroids may increase potential for healing problems.

Pharmacological Class:

NSAID.

Adverse Reactions:

Burning, stinging, dry eye, other ocular effects, increased bleeding (including hyphemas).

Generic Availability:

YES

How Supplied:

Soln—5mL

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs